Loading...
•
Jun 30, 2020
Surmodics Q3 2020 Earnings Report
Reported revenue increase of 10% year-over-year and GAAP EPS of $0.18.
Key Takeaways
Surmodics reported a revenue increase of 10% year-over-year, with GAAP EPS at $0.18 and non-GAAP EPS at $0.21. The company achieved critical milestones with CE Mark for SurVeil DCB and FDA clearance for Sublime PTA balloon catheter.
Revenue increased by 10% year-over-year.
GAAP EPS was $0.18, and non-GAAP EPS was $0.21.
CE Mark was received for SurVeil drug coated balloon (DCB).
FDA clearance was received for Sublime radial-access 0.014” PTA balloon catheter.
Surmodics
Surmodics
Surmodics Revenue by Segment
Revenue by Segment
Medical Device Revenue
CapyFin.comIn Vitro Diagnostics Revenue
CapyFin.com Forward Guidance
Due to the continued uncertainty surrounding the duration and magnitude of the COVID-19 pandemic, the Company will not provide financial guidance at this time.
Revenue & Expenses
Visualization of income flow from segment revenue to net income